AstraZeneca prices €2.55bn euro bond sale across four tranches

Finance Financial Services Written by: Ian Lyall 07:32 Tue 25 Aug 2026 --> Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Morgan Stanley ( NYSE:MS ) View Price & Profile AstraZeneca prices €2.55bn euro bond sale across four tranches Published: 07:32 25 Aug 2026 BST AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) , the FTSE 100 pharma group, has priced a €2.55 billion bond offering, tapping the euro debt market for general corporate purposes. The notes were issued on Monday by AstraZeneca Finance LLC, a wholly owned US subsidiary, and carry a full and unconditional guarantee from the parent company. The sale was split across four fixed rate tranches with maturities stretching from 2030 to 2038. The largest is a €750 million tranche maturing on 1 September 2038 with a coupon of 4.169%. A €700 million tranche maturing in March 2030 pays 3.402%, the cheapest money in the deal. The remaining two tranches comprise €600 million maturing in 2032 at 3.652% and €500 million maturing in 2035 at 3.923%. The pricing curve reflects the standard pattern of investors demanding higher returns for lending over longer periods. AstraZeneca described the issuance as consistent with its long-term funding strategy and said proceeds would go towards general corporate purposes rather than any specific project or acquisition. The company has been an active borrower in recent years as it funds an expanding pipeline and a series of manufacturing commitments, including substantial investment in the United States. The notes are being issued under the euro medium-term note programme, a standing framework that allows a company to issue debt repeatedly without drafting fresh documentation each time. They will be listed on the Financial Conduct Authority's Official List and admitted to trading on the London Stock Exchange's main market. Barclays, Goldman Sachs International and Morgan Stanley (NYSE:MS) acted as joint book-running managers. Continue reading